Preferred Label : elbasvir-grazoprevir drug combination;
MeSH synonym : elbasvir grazoprevir drug combination; elbasvir, grazoprevir drug combination;
Origin ID : C000611265;
UMLS CUI : C4080453;
ATC code(s)
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3478084/fr/zepatier-elbasvir/grazoprevir-hepatite-c-chez-les-adolescents-a-partir-de-12-ans
2024
false
false
false
France
evaluation of the transparency committee
adolescence
Hepatitis C Virus
hepatitis C
viral hepatitis c
Elbasvir/Grazoprevir
adolescent
Zepatier
Autonomic Nervous System
Teenager
Twelve
elbasvir-grazoprevir drug combination
Adolescents
Adolescent
Hepatitis C Infection
Algeria
---
https://www.has-sante.fr/jcms/p_3299682/fr/zepatier-grazoprevir-monohydrate/-elbasvir
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
elbasvir-grazoprevir drug combination
elbasvir
grazoprevir
drug combinations
administration, oral
adult
hepatitis C, chronic
antiviral agents
elbasvir and grazoprevir
evaluation of the transparency committee
---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal
product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds
---
https://www.ema.europa.eu/medicines/human/EPAR/Zepatier
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
drug approval
europe
elbasvir
elbasvir
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
adult
hepatitis C, chronic
antiviral agents
viral vaccines
Hepatitis C virus subtype 1a (organism)
Hepatitis C virus subtype 1b (organism)
Hepatitis C virus genotype 4 (organism)
administration, oral
drug antagonism
drug evaluation, preclinical
NS-5a protein, hepatitis C virus
protease inhibitors
protease inhibitors
NS3 protein, hepatitis C virus
NS4A cofactor peptide, hepatitis C virus
drug therapy, combination
elbasvir-grazoprevir drug combination
elbasvir and grazoprevir
NS-5 protein, hepatitis C virus
quinoxalines
quinoxalines
benzofurans
imidazoles
viral nonstructural proteins
carrier proteins
benzofurans
imidazoles
benzofurans
imidazoles
quinoxalines
---
http://www.has-sante.fr/portail/jcms/c_2724390/fr/zepatier
http://www.has-sante.fr/portail/jcms/c_2724390/fr/zepatier-elbasvir/grazoprevir-association-fixe-d-antiviraux-a-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
elbasvir
elbasvir
drug combinations
antiviral agents
antiviral agents
hepatitis C, chronic
administration, oral
benzofurans
benzofurans
imidazoles
imidazoles
quinoxalines
quinoxalines
treatment outcome
adult
hepatitis C, chronic
insurance, health, reimbursement
guidelines for drug use
elbasvir-grazoprevir drug combination
elbasvir-grazoprevir drug combination
elbasvir and grazoprevir
drug combinations
drug combinations
---
